TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06653946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Following the guidelines set by the American Heart Association/American Stroke Association (AHA/ASA), inclusion and exclusion criteria for alteplase were established; 0.9 mg/kg of alteplase up to a maximum dose of 90 mg was administered intravenously to eligible individuals within 4.5 hours of the beginning of their clinical manifestations (10% bolus, 90% infusion in 1 hour). After receiving IV-alteplase, all patients continued their management and rehabilitation in the stroke unit
Study: NCT05741918

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fick's method
Description: Cardiac output measurement by Fick method

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Cardiac output measurement by echocardiography
Study: NCT06656910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Compassion Group
Description: A 7-week self-compassion Programme:~Course 1:~Detective Warm-Up Game, Explaining the application of compassion/self-compassion.~Course 2:~Draw and Tell Warm-up Game, Breath Awareness Exercise, Mindful Eating Activity.~Course 3:~Walking Warm-Up, Body Scan Meditation, How Do You Treat Your Friend Activity.~Course 4:~Random Cards warm-up game, Compassion Meditation, Just Like Me Exercise.~Course 5:~Break, Self-compassionate letter writing.~Course 6:~Tree Drawing Warm-Up Game, Mountain Meditation, Recognize Your Inner Bully, Three Calming Breathing Exercises.~Course 7:~Considering the process with participants, Implementation of final tests, Tender farewell.
Study: NCT06663410

Intervention type: DEVICE
Intervention: SPG block with the use of the Tx360 device
Description: A SPG block was performed using the Tx360 nasal applicator according to the manufacturer's instructions bilaterally, injecting 0.3cc of lidocaine 2% into each nostril.
Study: NCT06663618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednison
Description: Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednison
Description: Oral prednison starts at 0.6-0.8mg/kg/d, then tapered and withdrawal in 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Oral Mycophenolate mofetil 0.75g bid for 6 months.
Study: NCT06663917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental frequency allocation table (FAT) - 438 Hz
Description: The modified cochlear implant program (experimental FAT) changes which frequencies are presented to the cochlear implant. The experimental FAT frequency of 438 Hz will be loaded onto the subjects processor via the CI Select Mobile App. Subjects will use the experimental FAT for one month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard FAT - 188 Hz
Description: All subjects will retain one program with the standard 188 Hz FAT. Subjects will use the standard FAT for one month.
Study: NCT06663124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EC-DBS ON
Description: The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy.The targets used in this study are extreme capsule.The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
Study: NCT06663085

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Enteral feeding
Description: intervention group received enteral feeding breastmilk during transfusion
Study: NCT06493513

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 40Hz stimulation
Description: Exogenous 40Hz stimulation is a physical intervention that induces gamma oscillations, oscillations and pulsations at the corresponding frequency, and may lead to a significant reduction in β-amyloid, reversal of tau protein hyperphosphorylation, and consequently improvement of cognitive function in patients.
Study: NCT06661993

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo film-coated tablet orally or via a nasogastric tube for seven days .

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-lipoic acid
Description: Alpha-lipoic acid 1800 mg orally or via a nasogastric tube for seven days .
Study: NCT06662578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional memory workshop
Description: The participants received 8 weekly sessions of 60 minutes of neurocognitive stimulation, based on French memory workshops.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Equine assisted therapy memory workshops
Description: The participants received 8 weekly sessions of 60 minutes, based on traditional memory workshops (French type of neurocognitive stimulation) with the mediation of a horse (example : working on associative memory by selecting which object is used for the horse between 2 presented objects).
Study: NCT05459077

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Hypertension control through education and monitoring
Description: Enrollment of 60 PLWH ≥18 years old receiving care at the Duke ID clinic who have achieved HIV viral suppression who take antihypertensive medication and have uncontrolled blood pressure. Subjects will have be given educational materials, blood pressure monitors to use and report findings, follow up with study coordinator and communication with subject's HIV provider in order to maximize blood pressure control..
Study: NCT05151991

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic treatment with stainless steel brackets
Description: Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy); brackets will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste will be removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). The following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic treatment with ceramic brackets
Description: Orthophosphoric acid 37% acid (Gerhò Etchant gel 37%, Gerhò spa, Terlano, Italy) will be applied for 30 s for the etching of the vestibular surfaces of teeth. The, after rinsing and drying, a thin layer of Transbond XT Light Cure Adhesive Primer (3M Unitek, Monrovia, CA, USA) will be applied and then cured for 10 s with a LED unit. At last, Transbond XT Light Cure Adhesive Paste (3M Unitek) will be applied on the base of ceramic brackets; brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth with a light pressure and the extra paste is removed. Curing will be performed with the LED unit at 2 mm distant from the enamel-bracket interface for 40 s, 10 s per each surface (mesial, distal, gingival and occlusal). Then, the following sequence of archwires will be adopted for the first six months: 0.012-in Niti, 0.014-in Niti, 0.016-in NiTi, 0.018 SS, 0.020 SS, 0.017X0.025-in NiTi, 0.019X0.025-in SS
Study: NCT06587347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban Hydrochloride
Description: Tirofiban will use a loading dose, 0.4 μg/kg/min × 30 minutes, then 0.1μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy, or use a loading dose, 25 μg/kg, administrated within 3 minutes, then 0.15μg/kg/min infusion until 24 hours after Intravenous thrombolytic therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment (SMT)
Description: Patients will receive standard antiplatelet therapy.
Study: NCT05247190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treating self-criticism
Description: A psychological treatment given i a group format targeting self-criticism. The treatment is based on treatment principles from Cognitive behavior therapy, Self-compassion, Acceptance and Commitment Therapy and also contains psychoeducation. The group treatment consists of 8 sessions delivered once a week for 2 hrs during 8 weeks in a child- and adolescent psychiatric outpatient setting.
Study: NCT04581499

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: DynamiCare Motivation Support Program
Description: DynamiCare is an evidence-based, multi-service platform that combines software, smartphone and pocket-sized alcohol and drug testing hardware, and recovery services, designed to remotely deliver evidence-based methodologies to facilitate people's motivation and accountability to overcome alcohol, nicotine and other drug use disorders, whether in formal treatment or not.

Intervention type: OTHER
Group type: OTHER
Intervention: Untreated or Routine Care Control Group
Description: No specific intervention, i.e., research participation plus any community-based treatment the individual seeks to obtain.
Study: NCT06304337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New oropharyngeal airway group
Description: Oropharyngeal airwayIt is composed of nasal plug, bite mouth, oropharyngeal passage, oxygen supply tube, rope and optional accessories carbon dioxide gas catheter and carbon dioxide collection tube.For patients undergoing endoscopic surgery/examination to prevent airway obstruction caused by backtongue fall, establish oropharyngeal airway for patients, and provide nasal oxygen at the same time, JK model can monitor oropharyngeal end-expiratory carbon dioxide collection.
Study: NCT06295549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LUCAR-G39P cells product
Description: LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
Study: NCT05597527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzopari and apatinib
Description: Fluzopari was used as 100mg capsules orally twice a day (one time in the morning and one time in the evening), every four weeks as a cycle, a total of 3-4 cycles. Apatinib was used as 250 mg orally once a day, every 4 weeks as a cycle, 2-3 cycles in total, and stop 4 weeks before operation.
Study: NCT04898790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS-II adapted to adults 60+ years in HCT setting
Description: CHAMPS-II is an evidence-based physical activity program designed to increase physical activity in sedentary older adults with multiple chronic health conditions. This is an individually tailored program that provides information, skills, training, and problem-solving support to older adults. Participants will engage in progressive, light to moderate-intensity physical activity throughout the HCT process, with the support of physical therapists, physical activity counselors, and their care-partner. They will take part in supervised exercise sessions; unsupervised exercise sessions; counseling sessions to address barriers, motivators, goals, and safety; and receive telephone support. Walking is the primary mode of aerobic activity, with training in flexibility, strengthening and balance exercises also included. An exercise kit will be provided, consisting of an intervention workbook, therapeutic resistance bands, and activity logs.
Study: NCT04668326

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Standing Wheelchair
Description: Mobile in seated position; Not mobile in standing position

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Manual Standing Wheelchair
Description: Mobile in BOTH seated and standing positions
Study: NCT04196556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Families
Description: This intervention, based on the methodology of meaningful learning, will have two components: group education aimed at parents (caregivers) and and education directed to children in the reviews in consultation. Group education (caregivers) groups will consist of 6 sessions, which will be given every two weeks, as determined in the program's follow-up annex, in the 3 months after the initial assessment. The content of the sessions is defined in attached annex. Regarding the proposed methodology, it has nuances and tools different from the traditional ones to achieve significant learning in the field of health. It is based on participatory methods and a more profound modification of knowledge, skills, emotions and attitudes than the brief advice that is used in family intervention in scheduled consultations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Madrid's Primary Healthcare Standardized Service portfolio
Description: An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Madrid's Primary Healthcare Standardized Service portfolio
Description: An anamnesis or functional assessment on the following aspects:~o Family history of obesity up to 2nd degree inbreeding. o Nutritional status - metabolic that includes at least no meals/day and daily consumption of liquids, fruits, vegetables, dairy, fats and sugars. o Activity - exercise that includes at least the type and intensity of exercise and time spent on sedentary activities (television, video games or the like). o Self-concept that includes at least the existence or not of behavioral problems and body image problems. o Role - relationships that include at least the performance of extracurricular activities.~A care plan in relation to identified problems and/or situations reviewed on a biannual basis.~They will be supplemented with the study-specific variables listed in the data collection notebook.
Study: NCT05698095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-methoxy-N,N-dimethyltryptamine succinate salt
Description: The 5-MeO-DMT drug product is comprised of the appropriate concentration of 5-MeO-DMT succinate salt drug substance in solution with 0.9% sodium chloride injection solution (USP) in a 5 mL glass vial, and is administered intramuscularly.
Study: NCT06137339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avocado Group
Description: Participants will consume provided avocados daily and track consumption for the duration of the study. Participants will be adding avocados to their diet and will receive education on maintaining usual diet.
Study: NCT06562673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar)
Description: After insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under local anesthesia, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Study: NCT05559242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride Capsule
Description: Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor
Study: NCT05519527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 (STI-6129)
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1 (STI-6129)
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (STI-6129)
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 (STI-6129)
Description: Given by vein (IV)
Study: NCT06539585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meiotic spindle status observation in polarized light
Description: In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meiotic spindle status observation in polarized light
Description: In patients older than 35 years and younger than 40 years, we will use a microscope with a polarizing filter to evaluate the position of meiotic spindles and polar bodies in oocytes collected from patients who were indicated for IVF and ICSI. Using an optical microscope with a Nikon CEE GmbH polarizing filter, the angle between PB and MS together with MS visibility will be determined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICSI
Description: ICSI will be performed according to standard protocol using ICSI/holding micropipettes (#002-5-30/#001-120-30, Microtech IVF, Czech Republic), polyvinylpyrrolidone (ICSI™, Vitrolife, Sweden), and Eppendorf (Hamburg, Germany) micromanipulation system equipped with thermoplate (Tokaohit, Japan). The oocytes will be cultivated individually, and their order preserved, so that the other outcomes (data from timelapse, clinical results) can be associated with individual oocytes. Oocytes will be denuded (HYASE-10X™, Vitrolife, Sweden) after OPU, and the maturation stage will be examined.
Study: NCT06500026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06263543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: IV infusion of 10 mg/kg on Days 1 and 8 of each continuous and consecutive 21-day cycles. The first infusion will last approximately 3 hours and subsequent infusions will last 1-2 hours if prior infusions were well tolerated.
Study: NCT05698095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is commercially available 0.9% sodium chloride solution (USP) for injection. The placebo is provided by the pharmacy in single-use sterile syringes of the appropriate dose.
Study: NCT05597007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPICS Clinic
Description: Participants will complete a mix of mandatory synchronous and asynchronous sessions with their Health Group to address PICS. Participants will spend 15 minutes daily on physiotherapy, and 15 minutes on cognitive therapy. There are also 2h time slots everyday for participants to join for an optional check-in with their health coach, who can support them in their individual activities. Participants will spend 15 minutes weekly responding to journal prompts about nutrition and general challenges.
Study: NCT05508113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone autohemotherapy
Description: After autologous blood is mixed with ozone in vitro, the blood is injected into the patient through intravenous infusion
Study: NCT06540677

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musical training
Description: Musical training with Meludia software, an online self-paced music training application